Analysis
Look across just this week's IPO calendar and a pattern emerges that's sharper than any single deal: public markets are pricing AI-adjacent and differentiated clinical-stage biotech names in an entirely different tier than established consumer and franchise brands. Scribe Therapeutics popped nearly 67% on its late-July Nasdaq debut. CXMT surged 466% in its Shanghai listing, becoming mainland China's most valuable listed company in a single session. Zhongji Innolight raised $6.8 billion in Hong Kong's biggest share sale in seven years. Meanwhile, Jersey Mike's opened as much as 9% below its IPO price before a partial recovery, and Reformation opened exactly flat at the bottom of its pricing range.
This isn't a story about execution quality. Jersey Mike's and Reformation both priced within or at the edge of their marketed ranges -- bankers read demand correctly going in. The divergence shows up specifically on debut day, in how much additional premium public investors are willing to pay once shares actually start trading. AI infrastructure, chip-adjacent, and differentiated clinical-stage biotech get that premium; understandable, profitable, but conventionally-growing consumer and franchise businesses don't, even when investors clearly want the deal to get done.
“Jersey Mike's and Reformation both priced within or at the edge of their marketed ranges -- bankers read demand correctly going in.”
The numbers back up that this is structural rather than a one-week fluke: 2026 IPO volume is already running 7.14% ahead of 2025's pace through July 29, and US biotech IPOs have averaged 55% returns this year against the broader IPO market's roughly -4.4% average -- a gap wide enough that it's shaping how bankers advise founders on pricing and timing across sectors, not just within biotech.
The real test of whether this AI premium holds is still ahead. OpenAI and Anthropic's looming trillion-dollar IPO race will price AI-lab economics at a scale several orders of magnitude larger than anything that's actually traded in 2026 so far -- Scribe's $155 million raise and CXMT's $8.6 billion offering are proof points, not stress tests, for what a $1 trillion-plus debut will look like. For VCs and LPs, this week's split-screen IPO calendar is the clearest evidence yet that sector, not just company quality, is now doing most of the work in determining debut-day returns.
